CN113133952A - Composition with skin-care and nutrition functions and preparation method thereof - Google Patents
Composition with skin-care and nutrition functions and preparation method thereof Download PDFInfo
- Publication number
- CN113133952A CN113133952A CN202110485065.XA CN202110485065A CN113133952A CN 113133952 A CN113133952 A CN 113133952A CN 202110485065 A CN202110485065 A CN 202110485065A CN 113133952 A CN113133952 A CN 113133952A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- weight
- mineral
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 153
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 21
- 230000035764 nutrition Effects 0.000 title claims description 16
- 230000006870 function Effects 0.000 title description 7
- 238000002360 preparation method Methods 0.000 title description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 64
- 239000011707 mineral Substances 0.000 claims abstract description 64
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 41
- 150000001413 amino acids Chemical class 0.000 claims abstract description 38
- 230000000694 effects Effects 0.000 claims abstract description 26
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical group CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 claims abstract description 23
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229940042585 tocopherol acetate Drugs 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 70
- 239000013522 chelant Substances 0.000 claims description 62
- 229940024606 amino acid Drugs 0.000 claims description 42
- 235000001014 amino acid Nutrition 0.000 claims description 37
- 239000011701 zinc Substances 0.000 claims description 36
- 229910052725 zinc Inorganic materials 0.000 claims description 36
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 35
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 35
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 35
- 229910052802 copper Inorganic materials 0.000 claims description 35
- 239000010949 copper Substances 0.000 claims description 35
- 239000011777 magnesium Substances 0.000 claims description 35
- 229910052749 magnesium Inorganic materials 0.000 claims description 35
- 229910052742 iron Inorganic materials 0.000 claims description 34
- 238000002156 mixing Methods 0.000 claims description 29
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 27
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000002366 mineral element Substances 0.000 claims description 26
- 229910052710 silicon Inorganic materials 0.000 claims description 26
- 239000010703 silicon Substances 0.000 claims description 26
- 239000004475 Arginine Substances 0.000 claims description 14
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 14
- 239000004471 Glycine Substances 0.000 claims description 14
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 14
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 14
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 14
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 14
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 14
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 14
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 14
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 14
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 14
- 239000004472 Lysine Substances 0.000 claims description 14
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 14
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 14
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 14
- 239000004473 Threonine Substances 0.000 claims description 14
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 14
- 235000004279 alanine Nutrition 0.000 claims description 14
- 235000009697 arginine Nutrition 0.000 claims description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 14
- 235000003704 aspartic acid Nutrition 0.000 claims description 14
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 14
- 235000018417 cysteine Nutrition 0.000 claims description 14
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 14
- 235000013922 glutamic acid Nutrition 0.000 claims description 14
- 239000004220 glutamic acid Substances 0.000 claims description 14
- 235000014304 histidine Nutrition 0.000 claims description 14
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 14
- 235000014705 isoleucine Nutrition 0.000 claims description 14
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 14
- 229960000310 isoleucine Drugs 0.000 claims description 14
- 235000005772 leucine Nutrition 0.000 claims description 14
- 235000018977 lysine Nutrition 0.000 claims description 14
- 235000006109 methionine Nutrition 0.000 claims description 14
- 229930182817 methionine Natural products 0.000 claims description 14
- 235000008729 phenylalanine Nutrition 0.000 claims description 14
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 14
- 235000013930 proline Nutrition 0.000 claims description 14
- 235000004400 serine Nutrition 0.000 claims description 14
- 235000008521 threonine Nutrition 0.000 claims description 14
- 235000002374 tyrosine Nutrition 0.000 claims description 14
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 14
- 235000014393 valine Nutrition 0.000 claims description 14
- 239000004474 valine Substances 0.000 claims description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
- 150000001879 copper Chemical class 0.000 claims description 7
- 229910021331 inorganic silicon compound Inorganic materials 0.000 claims description 7
- 159000000003 magnesium salts Chemical class 0.000 claims description 7
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 6
- 150000002505 iron Chemical class 0.000 claims description 6
- 150000003751 zinc Chemical class 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 230000001815 facial effect Effects 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 230000003647 oxidation Effects 0.000 abstract description 6
- 238000007254 oxidation reaction Methods 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 4
- 238000012423 maintenance Methods 0.000 abstract description 2
- 235000010755 mineral Nutrition 0.000 description 44
- 210000003491 skin Anatomy 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 16
- 230000002087 whitening effect Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- -1 zinc salts Chemical class 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005842 biochemical reaction Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 229940120145 3-o-ethylascorbic acid Drugs 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- VNXWANZMRATDQM-UHFFFAOYSA-N 2-(2-phenylethyl)benzene-1,3-diol Chemical compound OC1=CC=CC(O)=C1CCC1=CC=CC=C1 VNXWANZMRATDQM-UHFFFAOYSA-N 0.000 description 1
- JXPHIHWXMBYJAU-UHFFFAOYSA-N 7-methoxy-2,2-dimethyl-3,4-dihydrochromen-6-ol Chemical compound O1C(C)(C)CCC2=C1C=C(OC)C(O)=C2 JXPHIHWXMBYJAU-UHFFFAOYSA-N 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- BJRNKVDFDLYUGJ-ZIQFBCGOSA-N alpha-Arbutin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-ZIQFBCGOSA-N 0.000 description 1
- 229940033280 alpha-arbutin Drugs 0.000 description 1
- 239000008047 antioxidant nutrient Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940117973 dimethylmethoxy chromanol Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Abstract
The invention provides a composition with skin-care and nutritional effects, which comprises, by weight, 0.1-10 parts of vitamin C ethyl ether, 0.1-10 parts of vitamin E acetate, 0.1-10 parts of an amino acid composition and 0.1-10 parts of a mineral composition. The invention also provides a method for preparing the composition and a skin care product taking the composition as an active ingredient. The components of the composition of the invention participate in the maintenance of the health condition of the skin together through different principles, can play a role of synergy, obtains ideal overall skin care effect, and especially obtains ideal synergy effect in the aspects of removing oxidation free radicals, improving cell activity and the like.
Description
Field of the invention
The invention relates to a composition with skin-care and nutritional effects on skin and a preparation method thereof.
Background
In modern social life, people increasingly attach more importance to skin health, but at the same time, the deterioration of living habits and living environments of urban people brings challenges to the health condition of the skin. Therefore, more and more people are beginning to pay attention to maintaining or improving the health of skin by the action of exogenous active ingredients, wherein the aim of skin whitening is typical. Although the pigment content of the skin of each individual is determined by genetics, the scientific care of the skin with exogenous active ingredients in the future is still important for preventing the occurrence of melanin deposition, sunburn, spots, canceration and the like of the skin. Therefore, there is an increasing demand for products having skin whitening effects.
At present, products with skin whitening efficacy are various in types and different in formula. For example, in a whitening and spot-removing facial mask disclosed in patent document CN111568792A, an active ingredient having functions of resisting oxidation, scavenging free radicals, and the like (coenzyme Q10) and an active ingredient having a melanin synthesis-inhibiting function (acetylcysteine, α -arbutin, phenethylresorcinol, 3-o-ethyl ascorbic acid, and the like) are mainly compounded; the whitening composition disclosed in patent document CN106265365A adopts the extract of the ohuaxuedan and 3-o-ethyl ascorbic acid ether for compounding; the whitening and freckle-removing cream disclosed in patent document CN111249215A adopts dimethyl methoxy chromanol, vitamin C ethyl ether, arbutin and plum ferment decomposition product which are compounded to be used as whitening and freckle-removing active ingredients. These whitening products are desired to improve the whitening effect of the products by compounding various substances having melanin synthesis-inhibiting activity. Although the compounding of various whitening active ingredients can improve the overall whitening effect of the product to a certain extent, excessive pursuit of the compounding amount of the same functional components is formed, the active ingredients of the whitening product are more and more complicated, and the more the types of the active ingredients which are compounded together and can inhibit the synthesis of melanin are appeared, the higher the whitening effect of the product is. In fact, the whitening effect of the product cannot be obviously improved along with the increase of the types of active ingredients, so that the waste of the effects of the ingredients and the increase of the cost are caused, the stimulation to the skin is easily caused, and the sensitization risk is increased.
Therefore, there is a need to change the existing concept of whitening product formula, and pay attention to the complementation of the efficacy of the components in the formula to achieve the balance of the formula as a whole, thereby realizing the synergistic effect of the components in the formula.
Disclosure of Invention
Against this background, the present invention aims to: the composition has the skin-care nutrition effect on skin, not only has the whitening effect, but also has more balanced skin-care function on the whole.
Another object of the invention is also: articles for skin care containing the composition are provided.
Yet another object of the present invention is: methods of making the compositions are provided.
The technical scheme for realizing the purpose is as follows:
firstly, a composition with skin-care and nutritional effects is provided, which comprises 0.1 to 10 parts of vitamin C ethyl ether, 0.1 to 10 parts of vitamin E acetate, 0.1 to 10 parts of amino acid composition and 0.1 to 10 parts of mineral composition by weight.
The composition preferably comprises 1-8 parts of vitamin C ethyl ether, 0.5-3 parts of vitamin E acetate, 0.1-2 parts of amino acid composition and 0.8-6 parts of mineral composition in parts by weight.
More preferred compositions of the present invention comprise, by weight, 3 to 5 parts of vitamin C ethyl ether, 1 to 3 parts of vitamin E acetate, 0.5 to 1 part of an amino acid composition, and 0.8 to 3 parts of a mineral composition.
The most preferred composition of the present invention consists of, by weight, 3-4 parts of vitamin C ethyl ether, 2-3 parts of vitamin E acetate, 0.8-1 part of an amino acid composition, and 0.8-2 parts of a mineral composition.
In a preferred embodiment of the present invention, the amino acid composition is selected from the group consisting of any 2 or more of glycine, serine, glutamic acid, aspartic acid, leucine, alanine, lysine, arginine, tyrosine, phenylalanine, threonine, proline, valine, isoleucine, histidine, cysteine, and methionine; more preferably any 10 or more thereof; further preferably, the amino acid composition consists of the following amino acids in parts by weight: 48-50 parts of glycine, 25-28 parts of serine, 22-25 parts of glutamic acid, 14-16 parts of aspartic acid, 12-15 parts of leucine, 8-10 parts of alanine, 8-10 parts of lysine, 7-8 parts of arginine, 6-7 parts of tyrosine, 6-7 parts of phenylalanine, 5-6 parts of threonine, 5-6 parts of proline, 5-6 parts of valine, 5-6 parts of isoleucine, 2-4 parts of histidine, 2-3 parts of cysteine and 2-3 parts of methionine.
In the embodiment of the present invention, the mineral composition contains minerals that are not synthesized by the human body, preferably silicon, magnesium, copper, iron and zinc.
In a further preferred embodiment of the present invention, the mineral composition comprises the following mineral elements in the following weight ratio: silicon, magnesium, copper, iron and zinc in a ratio of 3-7:2-5:5-10:6-10: 20-30.
In a preferred embodiment of the present invention, the mineral composition has the following weight ratios of mineral elements: silicon, magnesium, copper, iron, zinc 4:4:8:8: 25.
In another preferred embodiment of the present invention, the mineral composition has the following weight ratios of mineral elements: magnesium, copper, iron, zinc 4:3:7:9: 28.
In another preferred embodiment of the present invention, the mineral composition has the following weight ratios of mineral elements: magnesium, copper, iron, zinc 5:3:8:9: 22.
In a further preferred embodiment of the present invention, the mineral composition has the following weight ratios of mineral elements: magnesium, copper, iron, zinc 4.5:3.5:7:8: 26.
In a more preferable scheme of the invention, in order to further improve the absorption efficiency of the skin on mineral trace elements and reduce cytotoxicity, each mineral in the mineral composition is a biological chelate formed by mineral elements and small molecular polypeptides; in a further preferred embodiment, the biological chelate is obtained by mixing and fermenting mineral inorganic salts (i.e. inorganic silicon compounds, inorganic magnesium salts, inorganic copper salts, inorganic iron salts and inorganic zinc salts) and yeast.
In a preferred embodiment of the invention, the vitamin E acetate is added in the form of liposome inclusion bodies in order to further improve the water solubility and the cell availability of the composition.
The present invention also provides a method for preparing the composition having skin care nutritional effects on the skin, comprising:
1) respectively mixing inorganic silicon compound, inorganic magnesium salt, inorganic copper salt, inorganic iron salt and inorganic zinc salt with yeast, and wrapping mineral element ions in organic matters secreted by the yeast through fermentation to respectively obtain silicon biological chelate, magnesium biological chelate, copper biological chelate, iron biological chelate and zinc biological chelate;
2) mixing the silicon biological chelate, the magnesium biological chelate, the copper biological chelate, the iron biological chelate and the zinc biological chelate obtained in the step 1) according to the weight ratio of silicon to magnesium to copper to iron to zinc of 3-7:2-5:5-10:6-10:20-30 to obtain a mineral composition;
3) mixing 48-50 parts of glycine, 25-28 parts of serine, 22-25 parts of glutamic acid, 14-16 parts of aspartic acid, 12-15 parts of leucine, 8-10 parts of alanine, 8-10 parts of lysine, 7-8 parts of arginine, 6-7 parts of tyrosine, 6-7 parts of phenylalanine, 5-6 parts of threonine, 5-6 parts of proline, 5-6 parts of valine, 5-6 parts of isoleucine, 2-4 parts of histidine, 2-3 parts of cysteine and 2-3 parts of methionine according to parts by weight to obtain an amino acid composition;
4) uniformly mixing vitamin C ethyl ether, vitamin E acetate, 3) obtained amino acid composition and 2) obtained mineral composition, and controlling the weight ratio of the components to be 0.1-10: 0.1-10: 0.1-10: 0.1 to 10; preferably, the weight ratio of the components is controlled to be 1-8: 0.5-3: 0.1-2: 0.8 to 6; most preferably 3 to 4: 2-3: 0.8-1: 0.8 to 2; the composition with skin care and nutrition effects on the skin is obtained.
The invention also provides a skin care product which takes the composition with skin care and nutrition effects on skin as an active ingredient. The skin care product can be skin lotion, essence, lotion, cream, eye cream, facial mask, etc.
The skin care product generally contains the active ingredient and corresponding auxiliary materials, and the auxiliary materials, taking essence as an example, can include disodium EDTA, 1, 3-propylene glycol, 1, 2-pentanediol, sodium hyaluronate, xanthan gum and the like.
In the composition, the vitamin C ethyl ether mainly plays a role in inhibiting melanin synthesis; the vitamin E acetate mainly plays a role in resisting free radical oxidative damage and promoting repair; the amino acid composition is used as an indispensable nutrient component of skin, and can help the skin to form natural moisturizing factors, inhibit cell shrinkage and looseness of stratum corneum, repair skin barrier defect, and maintain normal physiological state of the skin; the mineral composition is mainly used for avoiding nutrient substance imbalance caused by rapid consumption of the mineral, so that biochemical reactions in which other components in the composition play roles are smoothly carried out due to the participation of enough mineral components. On the basis, the selected minerals are all minerals which can not be synthesized by the human body, and have specific significance for the biochemical reaction of the skin. Wherein, the magnesium element can participate in enzyme reaction of carbohydrate and metabolism of protein and energy, and can maintain the integrity of tissue function and structure; the iron element helps to prevent fatigue and improve skin color; copper element is a cofactor of superoxide dismutase, is a key for absorbing and utilizing iron element, is helpful for oxidizing vitamin C and participates in the formation of elastin in the skin; silicon plays an important role in the formation of collagen and connective tissues, skin, etc.; the zinc element is an important antioxidant nutrient, has an important structural role in superoxide dismutase, and plays an important role in updating and healing the dermis. Based on the specific functions of the minerals, the inventor obtains the proper proportion of each mineral element in the mineral composition through a large number of experiments, so that the mineral composition has the optimal effect on maintaining the balance of nutrient substances, promoting the oxidation resistance, inhibiting the black synthesis and the like of biochemical reactions after being compounded.
In conclusion, the components of the composition of the invention participate in the maintenance of the health condition of the skin together through different principles, can play a role in synergy, and obtain ideal overall skin care efficacy, especially obtain ideal synergy effects in the aspects of scavenging oxidation free radicals, improving cell viability and the like.
Detailed Description
The technical solution and effects of the present invention will be described in detail below by way of examples, but the technical solution of the present invention is not limited to the examples.
Example 1
A composition with skin care and nutrition effects comprises, by weight, 8 parts of vitamin C ethyl ether, 3 parts of vitamin E acetate lipid inclusion, 1 part of amino acid composition and 2 parts of mineral composition. The 1 part of amino acid composition further comprises 49 parts by weight of glycine, 27 parts by weight of serine, 25 parts by weight of glutamic acid, 16 parts by weight of aspartic acid, 14 parts by weight of leucine, 9 parts by weight of alanine, 8 parts by weight of lysine, 7 parts by weight of arginine, 7 parts by weight of tyrosine, 6 parts by weight of phenylalanine, 6 parts by weight of threonine, 6 parts by weight of proline, 6 parts by weight of valine, 5 parts by weight of isoleucine, 3 parts by weight of histidine, 2 parts by weight of cysteine and 2 parts by weight of methionine; the 2 parts of mineral composition is formed by mixing a plurality of mineral elements and biological chelates formed by small molecular polypeptides respectively, wherein the mineral elements are as follows in weight ratio: silicon, magnesium, copper, iron, zinc 4:4:8:8: 25.
The composition described in this example can be prepared in the following manner:
1) respectively mixing inorganic silicon compound, inorganic magnesium salt, inorganic copper salt, inorganic iron salt and inorganic zinc salt with yeast, and wrapping mineral element ions in organic matters secreted by the yeast through fermentation to respectively obtain silicon biological chelate, magnesium biological chelate, copper biological chelate, iron biological chelate and zinc biological chelate;
2) mixing the silicon biological chelate, the magnesium biological chelate, the copper biological chelate, the iron biological chelate and the zinc biological chelate obtained in the step 1) according to the weight ratio of silicon to magnesium to copper to iron to zinc of 4:4:8:8:25 to obtain a mineral composition;
3) mixing 49 parts by weight of glycine, 27 parts by weight of serine, 25 parts by weight of glutamic acid, 16 parts by weight of aspartic acid, 14 parts by weight of leucine, 9 parts by weight of alanine, 8 parts by weight of lysine, 7 parts by weight of arginine, 7 parts by weight of tyrosine, 6 parts by weight of phenylalanine, 6 parts by weight of threonine, 6 parts by weight of proline, 6 parts by weight of valine, 5 parts by weight of isoleucine, 3 parts by weight of histidine, 2 parts by weight of cysteine and 2 parts by weight of methionine to obtain an amino acid composition;
4) uniformly mixing vitamin C ethyl ether, vitamin E acetate lipid inclusion, 3) obtained amino acid composition and 2) obtained mineral composition, and controlling the weight ratio of the components to be 8:3:1: 2; the composition with skin care and nutrition effects on skin is obtained.
Example 2
A composition with skin care and nutrition effects comprises, by weight, 5 parts of vitamin C ethyl ether, 3 parts of vitamin E acetate lipid inclusion, 0.5 part of amino acid composition and 0.8 part of mineral composition. The 0.5 part of amino acid composition further comprises 49 parts by weight of glycine, 27 parts by weight of serine, 25 parts by weight of glutamic acid, 16 parts by weight of aspartic acid, 14 parts by weight of leucine, 9 parts by weight of alanine, 8 parts by weight of lysine, 7 parts by weight of arginine, 7 parts by weight of tyrosine, 6 parts by weight of phenylalanine, 6 parts by weight of threonine, 6 parts by weight of proline, 6 parts by weight of valine, 5 parts by weight of isoleucine, 3 parts by weight of histidine, 2 parts by weight of cysteine and 2 parts by weight of methionine; the 0.8 part of mineral composition is formed by mixing a plurality of mineral elements and biological chelates formed by small molecular polypeptides respectively, wherein the mineral elements are as follows in weight ratio: magnesium, copper, iron, zinc 4:3:7:9: 28.
The composition described in this example can be prepared in the following manner:
1) respectively mixing inorganic silicon compound, inorganic magnesium salt, inorganic copper salt, inorganic iron salt and inorganic zinc salt with yeast, and wrapping mineral element ions in organic matters secreted by the yeast through fermentation to respectively obtain silicon biological chelate, magnesium biological chelate, copper biological chelate, iron biological chelate and zinc biological chelate;
2) mixing the silicon biological chelate, the magnesium biological chelate, the copper biological chelate, the iron biological chelate and the zinc biological chelate obtained in the step 1) according to the weight ratio of silicon to magnesium to copper to iron to zinc of 4:3:7:9:28 to obtain a mineral composition;
3) mixing 49 parts by weight of glycine, 27 parts by weight of serine, 25 parts by weight of glutamic acid, 16 parts by weight of aspartic acid, 14 parts by weight of leucine, 9 parts by weight of alanine, 8 parts by weight of lysine, 7 parts by weight of arginine, 7 parts by weight of tyrosine, 6 parts by weight of phenylalanine, 6 parts by weight of threonine, 6 parts by weight of proline, 6 parts by weight of valine, 5 parts by weight of isoleucine, 3 parts by weight of histidine, 2 parts by weight of cysteine and 2 parts by weight of methionine to obtain an amino acid composition;
4) uniformly mixing vitamin C ethyl ether, vitamin E acetate lipid inclusion, 3) obtained amino acid composition and 2) obtained mineral composition, and controlling the weight ratio of the components to be 5:3:0.5: 0.8; the composition with skin care and nutrition effects on skin is obtained.
Example 3
A composition with skin care and nutrition effects comprises, by weight, 4 parts of vitamin C ethyl ether, 3 parts of vitamin E acetate lipid inclusion, 1 part of amino acid composition and 1 part of mineral composition. The 1 part of amino acid composition further comprises 49 parts by weight of glycine, 27 parts by weight of serine, 25 parts by weight of glutamic acid, 16 parts by weight of aspartic acid, 14 parts by weight of leucine, 9 parts by weight of alanine, 8 parts by weight of lysine, 7 parts by weight of arginine, 7 parts by weight of tyrosine, 6 parts by weight of phenylalanine, 6 parts by weight of threonine, 6 parts by weight of proline, 6 parts by weight of valine, 5 parts by weight of isoleucine, 3 parts by weight of histidine, 2 parts by weight of cysteine and 2 parts by weight of methionine; the mineral composition of 1 part is formed by mixing a plurality of mineral elements and biological chelates formed by small molecular polypeptides respectively, wherein the mineral elements are as follows according to the weight ratio: magnesium, copper, iron, zinc 5:3:8:9: 22.
The composition described in this example can be prepared in the following manner:
1) respectively mixing inorganic silicon compound, inorganic magnesium salt, inorganic copper salt, inorganic iron salt and inorganic zinc salt with yeast, and wrapping mineral element ions in organic matters secreted by the yeast through fermentation to respectively obtain silicon biological chelate, magnesium biological chelate, copper biological chelate, iron biological chelate and zinc biological chelate;
2) mixing the silicon biological chelate, the magnesium biological chelate, the copper biological chelate, the iron biological chelate and the zinc biological chelate obtained in the step 1) according to the weight ratio of silicon to magnesium to copper to iron to zinc of 5:3:8:9:22 to obtain a mineral composition;
3) mixing 49 parts by weight of glycine, 27 parts by weight of serine, 25 parts by weight of glutamic acid, 16 parts by weight of aspartic acid, 14 parts by weight of leucine, 9 parts by weight of alanine, 8 parts by weight of lysine, 7 parts by weight of arginine, 7 parts by weight of tyrosine, 6 parts by weight of phenylalanine, 6 parts by weight of threonine, 6 parts by weight of proline, 6 parts by weight of valine, 5 parts by weight of isoleucine, 3 parts by weight of histidine, 2 parts by weight of cysteine and 2 parts by weight of methionine to obtain an amino acid composition;
4) uniformly mixing vitamin C ethyl ether, vitamin E acetate lipid inclusion, 3) obtained amino acid composition and 2) obtained mineral composition, and controlling the weight ratio of the components to be 4:3:1: 1; the composition with skin care and nutrition effects on skin is obtained.
Example 4
A composition with skin care and nutrition effects comprises, by weight, 1 part of vitamin C ethyl ether, 1 part of vitamin E acetate lipid inclusion, 1 part of amino acid composition and 1 part of mineral composition. The 1 part of amino acid composition further comprises 49 parts by weight of glycine, 27 parts by weight of serine, 25 parts by weight of glutamic acid, 16 parts by weight of aspartic acid, 14 parts by weight of leucine, 9 parts by weight of alanine, 8 parts by weight of lysine, 7 parts by weight of arginine, 7 parts by weight of tyrosine, 6 parts by weight of phenylalanine, 6 parts by weight of threonine, 6 parts by weight of proline, 6 parts by weight of valine, 5 parts by weight of isoleucine, 3 parts by weight of histidine, 2 parts by weight of cysteine and 2 parts by weight of methionine; the mineral composition is formed by mixing a plurality of mineral elements and biological chelates formed by small molecular polypeptides respectively, wherein the mineral elements are as follows in weight ratio: magnesium, copper, iron, zinc 4.5:3.5:7:8: 26.
The composition described in this example can be prepared in the following manner:
1) respectively mixing inorganic silicon compound, inorganic magnesium salt, inorganic copper salt, inorganic iron salt and inorganic zinc salt with yeast, and wrapping mineral element ions in organic matters secreted by the yeast through fermentation to respectively obtain silicon biological chelate, magnesium biological chelate, copper biological chelate, iron biological chelate and zinc biological chelate;
2) mixing the silicon biological chelate, the magnesium biological chelate, the copper biological chelate, the iron biological chelate and the zinc biological chelate obtained in the step 1) according to the weight ratio of silicon to magnesium to copper to iron to zinc of 4.5:3.5:7:8:26 to obtain a mineral composition;
3) mixing 49 parts by weight of glycine, 27 parts by weight of serine, 25 parts by weight of glutamic acid, 16 parts by weight of aspartic acid, 14 parts by weight of leucine, 9 parts by weight of alanine, 8 parts by weight of lysine, 7 parts by weight of arginine, 7 parts by weight of tyrosine, 6 parts by weight of phenylalanine, 6 parts by weight of threonine, 6 parts by weight of proline, 6 parts by weight of valine, 5 parts by weight of isoleucine, 3 parts by weight of histidine, 2 parts by weight of cysteine and 2 parts by weight of methionine to obtain an amino acid composition;
4) uniformly mixing vitamin C ethyl ether, vitamin E acetate lipid inclusion, 3) obtained amino acid composition and 2) obtained mineral composition, and controlling the weight ratio of the components to be 1:1:1: 1; the composition with skin care and nutrition effects on skin is obtained.
Example 5
The composition described in example 4 was used as an active ingredient to prepare an essence according to a conventional method, and the adopted raw materials and preparation method were as follows:
according to the parts by weight, 0.02 part of disodium EDTA, 2 parts of 1, 3-propylene glycol, 5 parts of 1, 2-pentanediol, 0.2 part of sodium hyaluronate, 0.1 part of xanthan gum and 4 parts of the composition prepared in example 4 are uniformly mixed, then deionized water is added to make the total amount reach 100 parts, and the essence is obtained after full stirring.
Experimental example 1 measurement of ROS scavenging Effect
In the experimental example, the oxidation resistance of a sample to be tested is evaluated by detecting the ROS content change after the sample acts under the UVB stimulation condition based on human keratinocyte, and the difference of the oxidation resistance between the compound raw materials and the single component is also compared and analyzed.
The cells used in this test were human keratinocytes (cell batch: Ep200708) obtained by cell primary culture and subculture from Guangdong Boxi Biotechnology Ltd.
The samples to be tested used in the test are the compositions of which the active ingredients are respectively the composition described in example 4 and the single component thereof, and the serial numbers and the concentrations of the active ingredients are shown in the following table 1:
table 1.
The experimental procedure was as follows:
1. cell inoculation: the cells were inoculated at 2.8E 5/well into 6-well plates and incubated overnight in an incubator (37 ℃ C., 5% CO 2).
2. Preparing liquid: the test article working solutions were prepared according to the experimental groups (table 3).
3. Administration: according to the experimental grouping design of table 3, when the plating rate of the cells in the 6-well plate reaches 40% -60%, the grouped drug delivery is carried out, the drug delivery amount of each hole is 2mL, and each group is provided with 3 multiple holes. The culture was continued for 24h in an incubator (37 ℃ C., 5% CO 2).
UVB irradiation: the group requiring UVB irradiation was subjected to UVB irradiation (irradiation dose 300mJ/cm2) in experimental groups (table 3).
And 5, detecting the content of ROS:
a) after irradiation, each well of cells was washed directly with PBS 3 times;
b) flow detection: adding 1mL of DCFH-DA probe in 10 μ M active oxygen kit to each well, and incubating in incubator (37 deg.C, 5% CO2, 95% RH) for 30 min; discarding culture solution containing DCFH-DA, washing with PBS for 3 times, after pancreatin (0.25%) digests cells, washing cells with PBS for 1 time, adding 0.5mL fresh PBS, and performing flow detection; c) and (4) analyzing results: the MFI (mean fluorescence intensity) of each group was pooled and subjected to statistical analysis.
The results are expressed as Mean ± SD using GraphPad Prism mapping. The comparison between groups was performed by statistical analysis of t-test. All statistical analyses were two-tailed. p <0.05 was considered to have significant differences, and p <0.01 was considered to have very significant differences.
Based on the test method, ROS content detection was performed, and the ROS content detection results are shown in tables 2 and 3:
TABLE 2 ROS content test results
| Sample name | ROS(MFI) | SD | p value |
| BC | 228341.50 | 9715.28 | / |
| NC | 313918.27 | 17823.15 | 0.002## |
| PC(VE) | 219371.83 | 5703.50 | 0.001** |
| #1VC Ethyl Ether | 250262.23 | 3505.28 | 0.004** |
| #3 amino acid composition | 231986.80 | 8798.65 | 0.002** |
| #4 mineral composition | 331876.57 | 16089.27 | 0.265 |
| #5VE acetate | 249954.27 | 6753.50 | 0.004** |
| Example 4 composition | 208095.93 | 7286.03 | 0.001** |
Compared with the BC group, the content of ROS in the NC group is obviously increased, which shows that the UVB stimulation in the experiment is effective.
The ROS content in the pc (ve) group was significantly reduced compared to the NC group, indicating that the positive control group was effective.
Compared with an NC group, the ROS content of a sample #1-VC ethyl ether, # 3-amino acid composition, #5-VE acetate and a compound raw material group is obviously reduced (p is less than 0.01); sample # 4-no significant change in ROS content of the mineral composition (p > 0.05).
TABLE 3 comparative analysis of ROS content variation between different feedstocks
| Sample name | ROS(MFI) | SD | p value |
| Example 4 composition | 208095.93 | 7286.03 | / |
| #1VC Ethyl Ether | 250262.23 | 3505.28 | 0.001** |
| #3 amino acid composition | 231986.80 | 8798.65 | 0.022* |
| #4 mineral composition | 331876.57 | 16089.27 | 0.000** |
| #5VE acetate | 249954.27 | 6753.50 | 0.002** |
The ROS content of samples #1-VC ethyl ether, # 3-amino acid composition, # 4-mineral composition, #5-VE acetate was all significantly increased compared to the sample group with the composition of example 4 as active ingredient (p < 0.05). It is demonstrated that the compositions of the present invention are superior to the single combination raw materials in terms of efficacy in scavenging ROS.
EXAMPLE 2 cell proliferation assay
1. Cell inoculation: the cells were inoculated at 4E 3/well into 96-well plates and incubated overnight in an incubator (37 ℃ C., 5% CO 2).
2. Preparing liquid: sample working solutions were prepared according to the experimental design (table 4).
TABLE 4 Experimental design
3. Administration: according to the experimental grouping design of table 4, when the plating rate of the cells in the 96-well plate reaches 20% -30%, the drug is administered in groups, the dose of each hole is 200 μ L, and each group is provided with 3 multiple holes. Incubator (37 ℃, 5% CO)2) Culturing for 24h, 48h and 72h respectively. Half-fluid change treatment was performed daily for groups requiring 48h and 72h of incubation.
4. And (3) detection: after the incubation and culture, the supernatant was discarded, MTT working solution (0.5mg/mL, ready for use) was added, incubation was carried out at 37 ℃ in the dark for 4h, after the incubation was completed, the supernatant was discarded, 150. mu. LDMSO was added to each well, and the OD was read at 490 nm. At the same time, after 48h and 72h, the MTT assay procedure described above was performed.
5. Calculating the relative activity of the cells: the relative cell viability (%) was calculated according to the formula. % 100 zeroing well-blank control well-sample well.
Cell proliferation efficacy assays were performed based on the above experimental methods, and the assay results are shown in tables 5 and 6:
TABLE 5 summary of cell proliferation assay results
Compared with the BC group, the cell viability of the PC group was significantly increased, indicating that the positive control group was effective.
Compared with a BC group, a sample # 3-amino acid composition and #5-VE acetate are compounded, the compound raw materials promote the keratinocyte proliferation in 24 hours, but have no significant keratinocyte proliferation promoting effect in 48 hours and 72 hours, and the #1-VC ethyl ether and # 4-mineral composition have no obvious keratinocyte proliferation promoting effect in 24 hours, 48 hours and 72 hours.
The cell proliferation rate was significantly increased in the PC group compared to the BC group, indicating that the positive control group was effective.
Compared with the BC group, the cell activity of the sample # 3-amino acid composition, #5-VE acetate and the compound raw material group is obviously improved.
TABLE 6 comparative analysis of cell viability changes between different feedstocks
The cell viability was significantly reduced in the #1-VC ethyl ether, # 4-mineral composition group compared to the sample group with the composition of example 4 as an active ingredient. It is demonstrated that the compositions of the present invention are superior to the single combination feed #1-VC ethyl ether and # 4-mineral compositions in promoting cell proliferation.
In summary, the compositions of the present invention are superior to the single starting materials #1-VC ethyl ether, # 3-amino acid composition, # 4-mineral composition and #5-VE acetate in terms of efficacy in scavenging ROS. The composition of the invention is superior to the single raw material of the #1-VC ethyl ether and the # 4-mineral composition in the aspect of promoting cell proliferation.
Claims (10)
1. A composition with skin care and nutrition effects comprises, by weight, 0.1-10 parts of vitamin C ethyl ether, 0.1-10 parts of vitamin E acetate, 0.1-10 parts of amino acid composition and 0.1-10 parts of mineral composition; preferably consists of 1 to 8 parts of vitamin C ethyl ether, 0.5 to 3 parts of vitamin E acetate, 0.1 to 2 parts of amino acid composition and 0.8 to 6 parts of mineral composition; more preferably 3-5 parts of vitamin C ethyl ether, 1-3 parts of vitamin E acetate, 0.5-1 part of amino acid composition and 0.8-3 parts of mineral composition; most preferably 3-4 parts vitamin C ethyl ether, 2-3 parts vitamin E acetate, 0.8-1 part amino acid composition and 0.8-2 parts mineral composition.
2. The composition of claim 1, wherein: the amino acid composition is selected from any 2 or more compositions of glycine, serine, glutamic acid, aspartic acid, leucine, alanine, lysine, arginine, tyrosine, phenylalanine, threonine, proline, valine, isoleucine, histidine, cysteine and methionine; more preferably any 10 or more thereof; further preferably, the amino acid composition consists of the following amino acids in parts by weight: 48-50 parts of glycine, 25-28 parts of serine, 22-25 parts of glutamic acid, 14-16 parts of aspartic acid, 12-15 parts of leucine, 8-10 parts of alanine, 8-10 parts of lysine, 7-8 parts of arginine, 6-7 parts of tyrosine, 6-7 parts of phenylalanine, 5-6 parts of threonine, 5-6 parts of proline, 5-6 parts of valine, 5-6 parts of isoleucine, 2-4 parts of histidine, 2-3 parts of cysteine and 2-3 parts of methionine.
3. The composition of any one of claims 1-2, wherein: the minerals in the mineral composition are composed of silicon, magnesium, copper, iron and zinc.
4. The composition of claim 3, wherein: the weight ratio of mineral elements contained in the mineral composition is as follows: silicon, magnesium, copper, iron and zinc in a ratio of 3-7:2-5:5-10:6-10: 20-30.
5. The composition of claim 3, wherein: the weight ratio of the mineral elements of the mineral composition is as follows: silicon, magnesium, copper, iron, zinc 4:4:8:8: 25.
6. The composition of claim 3, wherein: the weight ratio of the mineral elements of the mineral composition is as follows: magnesium, copper, iron, zinc 4:3:7:9: 28.
7. The composition of claim 3, wherein: the weight ratio of the mineral elements of the mineral composition is as follows: magnesium, copper, iron, zinc 5:3:8:9: 22.
8. The composition of claim 3, wherein: the weight ratio of the mineral elements of the mineral composition is as follows: magnesium, copper, iron, zinc 4.5:3.5:7:8: 26.
9. A method of preparing the composition having skin care nutritional efficacy on skin comprising:
1) respectively mixing inorganic silicon compound, inorganic magnesium salt, inorganic copper salt, inorganic iron salt and inorganic zinc salt with yeast, and wrapping mineral element ions in organic matters secreted by the yeast through fermentation to respectively obtain silicon biological chelate, magnesium biological chelate, copper biological chelate, iron biological chelate and zinc biological chelate;
2) mixing the silicon biological chelate, the magnesium biological chelate, the copper biological chelate, the iron biological chelate and the zinc biological chelate obtained in the step 1) according to the weight ratio of silicon to magnesium to copper to iron to zinc of 3-7:2-5:5-10:6-10:20-30 to obtain a mineral composition;
3) mixing 48-50 parts of glycine, 25-28 parts of serine, 22-25 parts of glutamic acid, 14-16 parts of aspartic acid, 12-15 parts of leucine, 8-10 parts of alanine, 8-10 parts of lysine, 7-8 parts of arginine, 6-7 parts of tyrosine, 6-7 parts of phenylalanine, 5-6 parts of threonine, 5-6 parts of proline, 5-6 parts of valine, 5-6 parts of isoleucine, 2-4 parts of histidine, 2-3 parts of cysteine and 2-3 parts of methionine according to parts by weight to obtain an amino acid composition;
4) uniformly mixing vitamin C ethyl ether, vitamin E acetate, 3) obtained amino acid composition and 2) obtained mineral composition, and controlling the weight ratio of the components to be 0.1-10: 0.1-10: 0.1-10: 0.1 to 10; preferably, the weight ratio of the components is controlled to be 1-8: 0.5-3: 0.1-2: 0.8 to 6; most preferably 3 to 4: 2-3: 0.8-1: 0.8 to 2; the composition with skin care and nutrition effects on skin is obtained.
10. A skin care product characterized by: the composition with skin care and nutrition effects on skin as claimed in claim 1 is used as an active ingredient; the skin care product is skin lotion, essence, emulsion, cream, eye cream or facial mask.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110485065.XA CN113133952A (en) | 2021-04-30 | 2021-04-30 | Composition with skin-care and nutrition functions and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110485065.XA CN113133952A (en) | 2021-04-30 | 2021-04-30 | Composition with skin-care and nutrition functions and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113133952A true CN113133952A (en) | 2021-07-20 |
Family
ID=76816824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110485065.XA Pending CN113133952A (en) | 2021-04-30 | 2021-04-30 | Composition with skin-care and nutrition functions and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113133952A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101282708A (en) * | 2005-10-05 | 2008-10-08 | 江崎格力高株式会社 | External preparation for skin containing a phosphorlated saccharide |
| CN106344424A (en) * | 2016-08-31 | 2017-01-25 | 百朗德生物化学(海门)有限公司 | Sun-proof, moisturizing and anti-aging amino acid cosmetic |
| CN111973497A (en) * | 2020-08-10 | 2020-11-24 | 合肥卡迪尔生物科技有限公司 | Composition for anti-wrinkle and tightening eye skin care product, anti-wrinkle and tightening eye skin care product and preparation method thereof |
| CN112438897A (en) * | 2019-09-05 | 2021-03-05 | 天津博纳戈恩生物科技有限公司 | Skin care composition with nourishing and skin-tendering effects |
| CN112618400A (en) * | 2021-01-29 | 2021-04-09 | 山东华熙海御生物医药有限公司 | Composition for improving skin color and whitening cosmetic |
-
2021
- 2021-04-30 CN CN202110485065.XA patent/CN113133952A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101282708A (en) * | 2005-10-05 | 2008-10-08 | 江崎格力高株式会社 | External preparation for skin containing a phosphorlated saccharide |
| CN106344424A (en) * | 2016-08-31 | 2017-01-25 | 百朗德生物化学(海门)有限公司 | Sun-proof, moisturizing and anti-aging amino acid cosmetic |
| CN112438897A (en) * | 2019-09-05 | 2021-03-05 | 天津博纳戈恩生物科技有限公司 | Skin care composition with nourishing and skin-tendering effects |
| CN111973497A (en) * | 2020-08-10 | 2020-11-24 | 合肥卡迪尔生物科技有限公司 | Composition for anti-wrinkle and tightening eye skin care product, anti-wrinkle and tightening eye skin care product and preparation method thereof |
| CN112618400A (en) * | 2021-01-29 | 2021-04-09 | 山东华熙海御生物医药有限公司 | Composition for improving skin color and whitening cosmetic |
Non-Patent Citations (1)
| Title |
|---|
| 上海禾雅堂医疗科技有限公司: "《https://hzpba.nmpa.gov.cn/gccx/chakanHis.html?prodId=20210407120554gsfo0&gb=G》", 10 March 2021, 国家药品监督管理局 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thakre | Formulation and development of de pigment serum incorporating fruits extract | |
| CN106333869A (en) | Skin care product having whitening and freckle removing effects and preparation method thereof | |
| CN113712874A (en) | Skin care product containing water-soluble silicon element and preparation method and application thereof | |
| KR101336804B1 (en) | Fermented ear shell using mushroom, manufacturing method thereof and cosmetic composition comprising the same | |
| KR20090111719A (en) | Cosmetic Compositions for whitening Skin containing jujube culture | |
| CN111956557A (en) | Composition and cosmetic with whitening and spot-fading effects and preparation method thereof | |
| KR20170143053A (en) | Cosmetic composition for improving anti-oxidation, anti-wrinkle and moisturizing comprising fermented product of used water from washing rice and preparation method of the same | |
| CN111000770A (en) | Whitening cream containing pearl peptide | |
| KR20110083480A (en) | Superoxide dismutase, radical scavenger, and cell disorder inhibitor by oxidation | |
| CN109875939A (en) | A kind of whitening spot-eliminating composition and its preparation method and application | |
| CN111329783B (en) | Composition for instantly brightening skin color and application thereof | |
| CN110559248B (en) | Skin-care matrix and preparation method and application thereof | |
| US20170281500A1 (en) | Vegfc production promoter | |
| CN113133952A (en) | Composition with skin-care and nutrition functions and preparation method thereof | |
| CN108338933A (en) | A kind of peptide composition and its application for whitening and reparation skin | |
| EP3112367A1 (en) | Use of metal complexes which are mimetics of sod as food agents and as cosmetics | |
| CN113749967B (en) | Peptide composition and application thereof | |
| CN112451438B (en) | Ginseng ferment and polypeptide composition | |
| KR101562368B1 (en) | Cosmetic composition comprising the biomimetic complex as active ingredient | |
| KR20130099277A (en) | A cosmetic composition comprising hydrolysates of ecklonia cava | |
| JP2020203930A (en) | Cosmetics | |
| CN113143818B (en) | Whitening and anti-photoaging composition and application thereof | |
| CN115770196B (en) | Multi-effect whitening and freckle-removing skin care product and preparation method and application thereof | |
| CN114796046B (en) | Whitening and freckle-removing antioxidant composition and application thereof | |
| CN113416764B (en) | Preparation method of mackerel antioxidant peptide and application of mackerel antioxidant peptide in mask |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210720 |
|
| RJ01 | Rejection of invention patent application after publication |